Table 1. Association between cfDNA concentration at pretreatment (T0) and clinicopathologic characteristics.

Patients with hormone receptor-positive HER2-negative (HR+HER2−) and triple-negative breast cancer (TNBC) were stratified into two groups, cfDNA high shedders vs. cfDNA low shedders, using median cfDNA concentration at pretreatment (T0) as the cutoff. Abbreviations: RCB-residual cancer burden, pCR-pathologic complete response

			cfDNA-high at T0		cfDNA-low at T0		Fisher p value
		Total	N	%	N	%
HR+HER2− (n=143, cutoff= 6.8297 ng/mL)
Clinical T stage (n=120)							0.8545
T1/T2		81	39	48.1	42	51.9
T3/T4		39	19	48.7	20	51.3
Clinical N stage (n=116)							0.8545
Node-negative		55	26	47.3	29	52.7
Node-positive		61	30	49.2	31	50.8
Grade (n=118)							0.1967
1/2		56	24	42.9	32	57.1
3		62	35	56.5	27	43.5
MammaPrint score (n=143)							1.0000
High 1		102	51	50.0	51	50.0
High 2		41	21	51.2	20	48.8
RCB class (n=142)							0.0993
RCB-0/pCR		22	9	40.9	13	59.1
RCB-I		10	2	20.0	8	80.0
RCB-II		61	36	59.0	25	41.0
RCB-III		49	25	51.0	24	49.0
TNBC (n=137; cutoff=6.2857 ng/mL)
Clinical T stage (n=123)							0.5532
T1/T2		87	42	48.3	45	51.7
T3/T4		36	20	55.6	16	44.4
Clinical N stage (n=118)							0.8538
Node-negative		62	30	48.4	32	51.6
Node-positive		56	29	51.8	27	48.2
Grade (n=105)							0.0134
1/2		12	2	16.7	10	83.3
3		93	52	55.9	41	44.1
MammaPrint score (n=137)							0.3002
High 1		16	6	37.5	10	62.5
High 2		121	63	52.1	58	47.9
RCB class (n=132)							0.7524
RCB-0/pCR		34	19	55.9	15	44.1
RCB-I		20	11	55.0	9	45.0
RCB-II		54	28	51.9	26	48.1
RCB-III		24	10	41.7	14	58.3